The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation
Open accessAbstract
Background: It has been proposed that treatments for irritable bowel syndrome with constipation (IBS-C) should provide rapid symptomatic relief, be intermittent, and effective upon repeated use. Aims: To evaluate the efficacy and safety of tegaserod on IBS symptoms, and its impact on quality of life and health economic measures. Patients: Women (⩾18 years of age) with IBS-C according to the Rome II criteria. Methods: Prospective, double blind, placebo controlled, randomised trial. Women with IBS-C either received tegaserod 6 mg twice daily or placebo for one month. Patients with at least a partial response entered a treatment free interval. Upon symptom recurrence, tegaserod treated patients were re-randomised to tegaserod or placebo for an additional month. Primary efficacy variables were response (overall IBS symptoms and abdominal discomfort/pain) to first and repeated treatment. Analysis was by intention to treat. Results: 2660 patients and 1191 patients were randomised for first and repeated treatment respectively. Tegaserod was superior to placebo for each primary efficacy variable (first treatment: 33.7% v 24.2% responders respectively for relief of IBS symptoms and 31.3% v 22.1% for relief of abdominal discomfort/pain; repeated treatment: 44.9% v 28.7%, and 42.4% v 27.1%, all p<0.0001). Tegaserod was superior to placebo for every secondary efficacy variable (relief of abdominal discomfort/pain, bloating and constipation; stool frequency and consistency). A response to tegaserod was observed within the first treatment week. Tegaserod produced greater satisfaction, work productivity, and improved quality of life than placebo (p<0.05). Conclusion: Tegaserod provides rapid and sustained relief of IBS-C symptoms both during first and repeated treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Patrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761 · cited 1×
“Additionally, patients completed the IBS-specific QoL questionnaire (IBS-QOL),[13] Work Productivity Activity Impairment for IBS with Constipation (WPAI:IBS-C)[14] and the health-related QoL EQ-5D[15,16] questionnaires at baseline and at the end of first and repeated treatment.”
MethodReilly, M. C., Bracco, A., Ricci, J. ‐., Santoro, J., & Stevens, T. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02091.x · Cited by 196 · cited 1×
“Additionally, patients completed the IBS-specific QoL questionnaire (IBS-QOL),[13] Work Productivity Activity Impairment for IBS with Constipation (WPAI:IBS-C)[14] and the health-related QoL EQ-5D[15,16] questionnaires at baseline and at the end of first and repeated treatment.”
MethodClinical trial guidelines for pharmacological treatment of irritable bowel syndrome
Corazziari, E., Bytzer, P., Delvaux, M., Holtmann, G., Malagelada, J. R., Morris, J., Muller‐Lissner, S., Spiller, R. C., Tack, J., & Whorwell, P. J. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01709.x · Cited by 80 · cited 2×
“Concerns have been raised previously regarding the design of IBS clinical trials that involve re-randomisation.[20] These concerns relate to the definition of recurrence and the possibility of treatment-related differences in the course of recurrence with the risk of subsequent re-randomisation compromising the treatm…”
BackgroundSelf-citationUsing the number needed to treat in clinical practice
Weeks, D. L., & Noteboom, J. T. (2004) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2004.03.025 · Cited by 29 · cited 1×
“7 NNT = numbers needed to treat[17] CI = confidence interval”
Background
Cited by
Serotonin, tryptophan metabolism and the brain-gut-microbiome axis
O’Mahony, S. M., Clarke, G., Borre, Y. E., Dinan, T. G., & Cryan, J. F. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.027 · Cited by 2,012
Gershon, M. D., & Tack, J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.002 · Cited by 1,563
Self-citationGuidelines on the irritable bowel syndrome: mechanisms and practical management
Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L., Hungin, P., Jones, R., Kumar, D., Rubin, G., Trudgill, N., et al. (2007) · Gut · doi:10.1136/gut.2007.119446 · Cited by 818
New Insights into the Placebo and Nocebo Responses
Enck, P., Benedetti, F., & Schedlowski, M. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.030 · Cited by 531
QUIGLEY, E. M. M., VANDEPLASSCHE, L., KERSTENS, R., & AUSMA, J. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03884.x · Cited by 344
Metadata
- Authors
- Tack, J., Müller-Lissner, S., Bytzer, P., Corinaldesi, R., Chang, L., Viegas, A., Schnekenbuehl, S., Dunger-Baldauf, C., & Rueegg, P.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2005-07-14
- Volume
- 54
- Issue
- 12
- Pages
- 1707-1713
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W1996393308
- Cited by
- 168
- References
- 5
- FWCI
- 14.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. https://app.cochat.ai/papers/10.1136/gut.2005.070789
- The paper
- Tack, J., Müller-Lissner, S., Bytzer, P., Corinaldesi, R., Chang, L., Viegas, A., Schnekenbuehl, S., Dunger-Baldauf, C., & Rueegg, P. (2005). A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut. https://doi.org/10.1136/gut.2005.070789
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.